International Network of Antibiotic Allergy Nations (iNAAN): Protocol for a type 2 hybrid effectiveness-implementation multicentre prospective cohort and target trial emulation study evaluating penicillin allergy delabeling via direct oral challenge
PLOS One · 2025
DOI: 10.1371/journal.pone.0330724 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS One, 2025. Verfasst von Elise A Mitri und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, at the Peter Doherty Institute for Infection and Immunology, Melbourne Medical School, University of Melbourne, Me…. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Penicillins, Anti-Bacterial Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council (NHMRC) Emerging Leadership Fellowship, PhD Scholarship from the Australian Government funded National Allergy Centre of Excellence.
Abstract (Originalsprache)
Background
Penicillin allergies are reported in 1 in 10 hospitalised patients globally and are associated with inferior patient and health service outcomes. However, more than 95% of low-risk penicillin allergies can be removed by direct oral challenge (DOC).
Objective
The International Network of Antibiotic Allergy Nations (iNAAN) aims to evaluate the utility of an audit and feedback (A&F) and education implementation strategy to increase the adoption of penicillin DOC in patients with a low-risk penicillin allergy, while concurrently assessing the impact of penicillin DOC on antibiotic prescribing and health service outcomes.
Methods
This is an international, multicentre type 2 hybrid effectiveness-implementation trial evaluating the widespread safety, clinical effectiveness and implementation of penicillin allergy delabeling via DOC, following penicillin allergy assessment using a purpose-built digital penicillin allergy toolkit within a smartphone application. The implementation strategy encompasses evaluation of co-designed digitally delivered bimonthly A&F reports to health services and clinicians, beginning a minimum of three months post site-activation, and optional education sessions that are delivered by the study team. The primary effectiveness outcome is the proportion of patients with a low-risk penicillin allergy that are delabeled following DOC. The primary implementation outcome is clinician adoption of the digital penicillin allergy toolkit within 6-months of site activation. Participants include adult patients who report a penicillin allergy and have undertaken a formalised penicillin allergy assessment, with or without DOC, at a participating health service. A target trial emulation approach will be used to analyse secondary effectiveness outcomes, including the impact of penicillin DOC on international antibiotic prescribing, infection-related and health service outcomes.
Discussion
This study protocol presents a type 2 hybrid effectiveness-implementation trial design that will provide high level evidence to aid widespread implementation of penicillin DOC.
Trial registration
ACTRN12623000484640 ( https://www.anzctr.org.au/ ) ( https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385815&isReview=true ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, at the Peter Doherty Institute for Infection and Immunology, Melbourne Medical School, University of Melbourne, Melbourne, Victoria, Australia.
- Centre for Antibiotic Allergy and Research, Department of Infectious Diseases and Immunology, Austin Health, Melbourne, Victoria, Australia.
- National Allergy Centre of Excellence (NACE), Parkville, Victoria, Australia.
- Department of Anaesthesia, Austin Health, Melbourne, Victoria, Australia.
- Department of Critical Care, University of Melbourne, Melbourne, Victoria, Australia.
- Data Analytics Research and Evaluation (DARE) Centre, Austin Health, Melbourne, Victoria, Australia.
ORCID-Profile: Elise A Mitri, Camille Paynter, Sara Vogrin
Förderung
- National Health and Medical Research Council (NHMRC) Emerging Leadership Fellowship
- PhD Scholarship from the Australian Government funded National Allergy Centre of Excellence
Zitieren
APA
Mitri, E. A., Fletcher, L. R., Paynter, C., Vogrin, S., James, F., Ng, I., Holmes, N. E., Ierano, C., Roberts, J. A., Fernando, S. L., Klaic, M., & Trubiano, J. A. (2025). International Network of Antibiotic Allergy Nations (iNAAN): Protocol for a type 2 hybrid effectiveness-implementation multicentre prospective cohort and target trial emulation study evaluating penicillin allergy delabeling via direct oral challenge. PLOS One. https://doi.org/10.1371/journal.pone.0330724
Vancouver
Mitri EA, Fletcher LR, Paynter C, Vogrin S, James F, Ng I, et al. International Network of Antibiotic Allergy Nations (iNAAN): Protocol for a type 2 hybrid effectiveness-implementation multicentre prospective cohort and target trial emulation study evaluating penicillin allergy delabeling via direct oral challenge. PLOS One. 2025. doi:10.1371/journal.pone.0330724
BibTeX
@article{Mitri2025,
author = {Mitri, Elise A and Fletcher, Luke R and Paynter, Camille and Vogrin, Sara and James, Fiona and Ng, Irvin and Holmes, Natasha E and Ierano, Courtney and Roberts, Jason A and Fernando, Suran L and Klaic, Marlena and Trubiano, Jason A},
title = {International Network of Antibiotic Allergy Nations (iNAAN): Protocol for a type 2 hybrid effectiveness-implementation multicentre prospective cohort and target trial emulation study evaluating penicillin allergy delabeling via direct oral challenge},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0330724}
}
EUVIMED